Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTHOUSE study of ATSN-201 for RS1-associated X-linked retinoschisis
2026-525886-38-00Phase 3Authorised
- Sponsor
- Atsena Therapeutics
- Start
- Sep 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of ATSN-201 in X-linked retinoschisis (XLRS) and Fundus dystrophy (3 arms), sponsored by Atsena Therapeutics. Primary endpoint: Change from baseline in microperimetry across prespecified loci in the study eye. Planned start Sep 2026; status: authorised.
02
Drugs
ATSN-201
03
Conditions
X-linked retinoschisis (XLRS)Fundus dystrophy
Beyond the preview
Go deeper on 2026-525886-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525886-38-00.